2025 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board OnDemand

2025 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

Course Description
This course explores the clinical significance of germline and somatic variants in cancer and provides practical knowledge on the application of clinical guidelines and bioinformatics tools for treatment recommendations. Participants will gain an understanding of how various disciplines—medical oncology, molecular pathology, genomics, bioinformatics, and genetic counseling—collaborate in cancer care. Emphasizing the importance of multi-institutional collaboration, the course covers workflows for cancer variant interpretation, including the utilization of genomic tumor boards and variant annotation pipelines.

Target Audience
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Webinar Series

January 28, 2025
Title: Cases in Precision Oncology: Highlights from the 2024 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

February 25, 2025
Title: Chromosomal Mimicry in Hematologic Malignancies

March 25, 2025
Title: Complementary Use of Circulating Tumor Cell Sequencing and Tumor Sequencing

Apri 22, 2025
Title: TBA

May 27, 2025
Title: TBA

June 24, 2025
Title: TBA

Learning Objectives
At the conclusion of this series, participants should be able to:
• Apply clinical guidelines and bioinformatics tools to determine the clinical significance of germline and somatic variants in cancer
• Describe the spectrum of resources to aid in cancer variant interpretation in the clinic
• Utilize genomic tumor boards informed by multiple workflows and annotation pipelines

Manuela Benary, PhD

Bioinformatician

Charité – Universitätsmedizin Berlin, Berlin, Germany

Beth Pitel, MS

Clinical Variant Scientist – Oncology

Assistant Professor of Laboratory Medicine and Pathology

Mayo Clinic

Jason Saliba, PhD

Senior Scientist at Washington University School of Medicine in St. Louis

	Gordana Raca, MD, PhD, FACMG Director, Clinical Cytogenomics Laboratory, Center for Personalized Medicine Professor of Clinical Pathology, Keck School of Medicine of USC Children’s Hospital of Los Angeles
	Adrian Dubuc, PhD, FACMG Vice-Chair, Cytogenetics/Genomics Clinical Research Director, Clinical Cytogenetics Laboratory Roswell Park Comprehensive Cancer Center
	Valentina Nardi, MD Associate Professor of Pathology – Massachusetts General Hospital
	Amir T. Fathi, MD Associate Professor of Medicine – Massachusetts General Hospital
	Gabriela S. Hobbs, MD Associate Professor of Medicine – Massachusetts General Hospital
	Scott T. Ryall, PhD Associate Pathologist – Brigham and Women’s Hospital Instructor in Pathology – Harvard Medical School
	Melissa M. Zhao, MD Clinical Fellow in Pathology – Brigham and Women’s Hospital

Nisha Kanwar, PhD
Laboratory Genetics and Genomics Fellow, Mayo Clinic
Department of Laboratory Medicine and Pathology

Planning Committee:
Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jason Saliba, PhD
Jane Radford, MHA, CHCP
Claudia Barnett

AMA PRA Category 1 CreditsTM & CME Other

Accreditation
The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.

Claiming your Educational Credits
This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit. If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.

Learner Data Consent
ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.

Technical Support:
You can reach us by email at education@acmg.net or call 301-718-9603.
Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure data updated 2/6/2025

NAME	ROLE			RELATIONSHIP/ COMPANY
	Planning Member	Presenter Panelist Moderator	Peer Reviewer
Manuela Benary, PhD	●	●		Speaker: Novartis
Beth Pitel, MS, CG(ASCP)	●	●		Advisory Board: Qiagen, LLC
Gordana Raca, MD, PhD, FACMG	●	●	●	Nothing to Disclose.
Jason Saliba, PhD	●			Nothing to Disclose.
Adrian Dubuc, PhD, FACMG		●		Noting to Disclose.
Amir Fathi, MD		●		Consultant: AbbVie, Amgen, Astellas Pharma, AstraZeneca, Autolus, Bristol-Myers Squibb, Daiichi Sankyo Co, Genentech, Gilead Sciences Inc., Ipsen Biopharmaceuticals, Inc., Kite Pharma. Inc. Kura Oncology, Menarini Group, Novartis, Orum, Pfizer, Prelude Therapeutics, Remix, Rigel Pharmaceuticals, Inc., Schrodinger, Servier Pharmaceuticals LLC, Syndax, Takeda Oncology Grant: Abbvie, Servier Pharmaceuticals LLC
Gabriela Hobbs, MD		●		Consultant: Abbvie. Bristol Myers Squibb, GlaxoSmithKline, Novartis, PharmaEssentia, Sobi Research: Incyte Corporation
Nisha Kanwar		●		Nothing to Disclose.
Valentina Nardi, MD		●		Nothing to Disclose.
Scott Ryall, PhD		●		Nothing to Disclose.
Melissa Zhao, MD		●		Nothing to Disclose.
Jane Radford, MHA, CHCP	●			Nothing to Disclose.
Claudia Barnett	●			Nothing to Disclose.